If the answer is yes, you’re not alone. A recent Hologic survey found that roughly two thirds of U.S. women (66%) say their period has impacted their day-to-day life, with nearly half (49%) saying they have leaked through their clothing1. While we understand that these are common experiences for so many women, we’re here to say, enough is enough – Better is Possible!  

Women are often told that painful periods, uncontrolled bleeding and debilitating discomfort are normal – a part of being a woman. But is that the truth? Should women have to suffer in silence? At Hologic, we believe that a better life is possible – better options, better care, better treatment, a better you. This belief is why Hologic is dedicated to changing the standard of care for women suffering from uterine fibroids and abnormal uterine bleeding (AUB) to truly consider your entire wellbeing.  
 
At Hologic we are passionate advocates for pioneering progress and setting new standards for women’s healthcare technology. Committed to excellence, we have embarked on a journey to redefine the treatment of uterine fibroids and abnormal uterine bleeding (AUB) through cutting-edge innovation. From state-of-the-art minimally invasive surgical tools to patient-centric methodologies, we are on a mission to revolutionize women’s health, ensuring that every woman receives the personalized, comprehensive care she deserves.  
 
Thanks to these technological advances, gone are the days when hysterectomy is the only treatment option for women suffering from fibroids and AUB. For example, laparoscopic radiofrequency ablation, also known as the Acessa® procedure, is a minimally invasive treatment option that delivers heat directly into a fibroid to treat the tissue and relieve your fibroid symptoms. Not to mention, these minimally invasive treatment options require much less down time allowing you to return to your normal life sooner than a hysterectomy. Learn more about Hologic’s treatment options the Acessa®, MyoSure® and NovaSure® procedures.

1 This survey was conducted online within the United States by The Harris Poll on behalf of Hologic between May 10-12, 2022 among 997 female adults ages 18+.